Literature DB >> 9258657

Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development.

A van den Berg1, T Dijkhuizen, T G Draaijers, M M Hulsbeek, E R Maher, E van den Berg, S Störkel, C H Buys.   

Abstract

Multiple renal cell tumours from three unrelated patients have been analysed for loss of heterozygosity of 3p, mutation of VHL, and chromosome 7 and 17 imbalances. Loss of 3p alleles is characteristic for clear cell type tumours and the combination of +7, +17 for chromophilic cell type tumours. Thus, we could classify adenomas and carcinomas of the three patients according to the genomic patterns of the tumours. Adenomas appeared to be mostly of the chromophilic cell type. In some adenomas, however, allelic losses of chromosome 3 were detected, pointing to a clear cell phenotype. Irrespective of showing loss or retention of the 3p25 region, none of the adenomas had a VHL mutation. Therefore, inactivation of VHL does not seem to be an early event in the development of renal cell tumours. Results of an analysis of regions of loss and retention of alleles of 3p markers in multiple tumours of the individual patients suggest that losses at either 3p25 or 3p12-p14 are associated with adenomas. Additional loss at 3p21 is most likely required to lead to development of a more malignant clear cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258657     DOI: 10.1002/(sici)1098-2264(199708)19:4<228::aid-gcc4>3.0.co;2-z

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.

Authors:  E R Woodward; S C Clifford; D Astuti; N A Affara; E R Maher
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

2.  The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.

Authors:  K Dreijerink; E Braga; I Kuzmin; L Geil; F M Duh; D Angeloni; B Zbar; M I Lerman; E J Stanbridge; J D Minna; A Protopopov; J Li; V Kashuba; G Klein; E R Zabarovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

3.  Renal cell neoplasms contain shared tumor type-specific copy number variations.

Authors:  John M Krill-Burger; Maureen A Lyons; Lori A Kelly; Christin M Sciulli; Patricia Petrosko; Uma R Chandran; Michael D Kubal; Sheldon I Bastacky; Anil V Parwani; Rajiv Dhir; William A LaFramboise
Journal:  Am J Pathol       Date:  2012-04-03       Impact factor: 4.307

Review 4.  VHL, the story of a tumour suppressor gene.

Authors:  Lucy Gossage; Tim Eisen; Eamonn R Maher
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

5.  Array-CGH and multipoint FISH to decode complex chromosomal rearrangements.

Authors:  Eva Darai-Ramqvist; Teresita Diaz de Ståhl; Agneta Sandlund; Kiran Mantripragada; George Klein; Jan Dumanski; Stefan Imreh; Maria Kost-Alimova
Journal:  BMC Genomics       Date:  2006-12-29       Impact factor: 3.969

6.  Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis.

Authors:  H-J Thiesen; F Steinbeck; M Maruschke; D Koczan; B Ziems; O W Hakenberg
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

7.  BAP1-Related ceRNA (NEAT1/miR-10a-5p/SERPINE1) Promotes Proliferation and Migration of Kidney Cancer Cells.

Authors:  Rui-Ji Liu; Zhi-Peng Xu; Shu-Ying Li; Jun-Jie Yu; Ning-Han Feng; Bin Xu; Ming Chen
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

8.  Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile.

Authors:  Ingrid Cifola; Roberta Spinelli; Luca Beltrame; Clelia Peano; Ester Fasoli; Stefano Ferrero; Silvano Bosari; Stefano Signorini; Francesco Rocco; Roberto Perego; Vanessa Proserpio; Francesca Raimondo; Paolo Mocarelli; Cristina Battaglia
Journal:  Mol Cancer       Date:  2008-01-14       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.